![](http://investorshub.advfn.com/images/default_ih_profile2_4848.jpg?cb=0)
Thursday, December 06, 2012 1:37:04 PM
Apricus shares have declined this year for several reasons, including but not limited to: 1) An after-effect from
the March 2012 equity raise; 2) A wait-and-see approach by investors related to the financial impact of the
recent acquisitions; 3) Expectations regarding the finalization of pricing and timing of product launch of Vitaros
in Canada; and/or 4) Uncertainties regarding management transition. Interestingly enough, APRI shares are now
trading at levels below our original recommendation in late 2010, and investors can still achieve considerable
share appreciation (100%+) at our current price target of $5.50 per share.
the potential catalysts for Apricus for the remainder of 2012 and into 2013 are:
1) Soft Launch of Vitaros in Canada by Abbott (H1/2013) targeted at urologists, more comprehensive launch
later next year (H2/2013);
2) Approval in Europe for Vitaros (end of 2012 or early 2013), additional potential partnerships signed in
Europe (Spain, Eastern Europe) 2012-2013;
3) Potential response to existing US FDA Complete Response Letter for Vitaros by partner Warner Chilcott
(Nasdaq/WCRX/Not Rated) late 2012 or early 2013, potential US approval 2013;
4) Additional country filings for Vitaros in Latin America and Rest-of-World, particularly Mexico (2012-
2013);
5) Availability of Room Temperature (RT) second generation formulation of Vitaros (Duoject) 2013;
6) Regulatory guidance by health agencies in the US, Europe and Canada for Femprox (H2/2012);
7) Regulatory guidance by health agencies in the US, Europe and Canada for MycoVa (H2/2012);
8) Re-launch of new manufactured batch of Totect (H2/2012), partnerships signed for Canadian and European
markets (2012-2013);
9) Initiation of pharmacokinetic bioequivalency trials for PrevOnco in H2/2012;
10) Initiation of clinical trials by partner Exodos for NexACT ibuprofen drug candidate in 2013; and
11) Filing in Europe and other territories for NitroMist, as well as potentially additional partnership activity for
this recently acquired product.
Recent SEEL News
- Form S-1 - General form for registration of securities under the Securities Act of 1933 • Edgar (US Regulatory) • 06/14/2024 08:06:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 06/05/2024 08:05:35 PM
- Form D - Notice of Exempt Offering of Securities • Edgar (US Regulatory) • 05/31/2024 08:30:38 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/21/2024 08:01:36 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 05/20/2024 08:16:07 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/16/2024 01:00:52 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/14/2024 03:45:26 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/14/2024 12:00:41 PM
- Form S-1/A - General form for registration of securities under the Securities Act of 1933: [Amend] • Edgar (US Regulatory) • 03/06/2024 10:32:04 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 03/06/2024 09:50:40 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/01/2024 10:39:18 PM
- Form SC 13G - Statement of acquisition of beneficial ownership by individuals • Edgar (US Regulatory) • 02/06/2024 10:26:45 PM
- Form S-1 - General form for registration of securities under the Securities Act of 1933 • Edgar (US Regulatory) • 02/02/2024 11:04:12 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/30/2024 09:01:23 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 01/30/2024 11:05:53 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/22/2024 01:05:21 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/18/2024 02:47:31 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/18/2024 02:47:06 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/10/2024 09:16:24 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/09/2024 02:46:09 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/09/2024 02:45:51 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/09/2024 02:45:30 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/09/2024 02:45:13 AM
- Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material • Edgar (US Regulatory) • 01/02/2024 01:10:24 PM
Green Leaf Innovations, Inc. Expands International Presence with New Partnership in Dubai • GRLF • Jun 24, 2024 8:30 AM
Bemax Inc. Positions to Capitalize on Industry Growth with New Improved Quality of Mother's Touch® Disposable Diapers • BMXC • Jun 24, 2024 8:00 AM
Last Shot Hydration Drink Announced as Official Sponsor of Red River Athletic Conference • EQLB • Jun 20, 2024 2:38 PM
ATWEC Announces Major Acquisition and Lays Out Strategic Growth Plans • ATWT • Jun 20, 2024 7:09 AM
North Bay Resources Announces Composite Assays of 0.53 and 0.44 Troy Ounces per Ton Gold in Trenches B + C at Fran Gold, British Columbia • NBRI • Jun 18, 2024 9:18 AM
VAYK Assembling New Management Team for $64 Billion Domestic Market • VAYK • Jun 18, 2024 9:00 AM